
Please try another search
Agenus Inc. (NASDAQ:AGEN) incurred loss of 37 cents per share in line with the Zacks Consensus Estimate. The figure came in narrower the year-ago loss of 47 cents.
Revenues of $3.4 million missed the Zacks Consensus Estimate of $4 million. Also, the top line was down from $4.4 million in the year-ago quarter.
So far this year, shares of Agenus have declined 15.1%, as against the industry’s growth of 3.3%.
Quarterly Highlights
Agenus' third-quarter research and development (R&D) expenses were up 19.5% to $25.8 million. However, general and administrative expenses were down slightly by 0.7% to $8.1 million.
Pipeline Update
Agenus is progressing well with various candidates in its pipeline. The company expects to complete phase I dose-escalation, and generate safety and pharmacodynamic data for its anti-CTLA-4 antibody AGEN1884 later in 2017. Also, it is planning to start combination trials of AGEN1884 and AGEN2034 by the year end.
Agenus separate business entity -AgenTus, will help enhance business focus, speed and efficiency towards the realization of breakthrough immuno-oncology drugs designed to cure patients with advanced cancers.
Zacks Rank and Key Picks
Agenus carries a Zacks Rank #2 (Buy).Some other top-ranked health care stocks in the same space include Ligand Pharmaceuticals Inc. (NASDAQ:LGND) , Exelixis, Inc. (NASDAQ:EXEL) and Adaptimmune Therapeutics plc (NASDAQ:ADAP) . While Ligand sports a Zacks Rank #1 (Strong Buy), Exelixis and Adaptimmune carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Ligand’s earnings per share estimates have moved up $3.68 to $3.70 for 2018 over the last 30 days. The company pulled off positive earnings surprises in two of the trailing four quarters, with an average beat of 6.19%. The share price of the company has increased 44% year to date.
Exelixis’ earnings per share estimates have moved up from 26 cents to 45 cents for 2017 and from 63 cents to 70 cents for 2018 over the last 30 days. The company delivered positive earnings surprises in all of the trailing four quarters, with an average beat of 572.92%. The share price of the company has increased 78.3% year to date.
Adaptimmune’s loss per share estimates have narrowed from 96 cents to 76 cents for 2017 and from 90 cents to 74 cents for 2018 over the last 60 days. The company came up with positive earnings surprises in two of the trailing four quarters, with an average beat of 24.79%. The share price of the company has increased 101.7% year to date.
Wall Street’s Next Amazon (NASDAQ:AMZN)
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Through many years of frustration among gold bugs due to the failure of gold stock prices to leverage the gold prices in a positive way, there were very clear reasons for that...
I know there is the smell of fear in the air when I see my readership double as we reach a point where weekly chart factors come into play. Up until last week, markets have...
Professional traders get paid because of one skill and one skill only: the ability to foresee what the world (or the economy, at least) might look like in six to nine months....
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.